Veeva Lifts Analyst Targets as Shorts Quietly Exit

Veeva Systems enters November with an unusual mix: short sellers cutting exposure at a meaningful pace, analysts pushing targets above the current price, and earnings nine days away. The stock closed at $313.46, down 1.6% on the week, underperforming its closest correlated peers whose median was up 0.4%.

The short-selling story is one of quiet retreat. Short interest dropped 10.7% over the past seven days to 2.5% of the free float, a level low enough to count as background noise for a company of this size. Borrowing the stock costs less than half a percent annualised, and availability is so ample that there are roughly 63 shares still available for every one already lent out, putting the borrow market about as loose as it gets. The ORTEX short score has edged lower over the same period, from 34.3 to 32.9, consistent with the direction of that covering. Options are broadly calm: the put/call ratio at 0.47 is only fractionally above its 20-day average, and well below the 0.69 peak of the past year. None of this points to a market leaning hard against the name.

The more interesting tension is between where the stock is trading and where analysts think it should trade. Two meaningful target raises arrived this week. Barclays lifted its target to $375 from $360 while holding its Overweight rating, a second raise from the same analyst in nine days after a prior move to $360 from $315. Baird went further, moving to $350 from $300 and keeping Outperform. Both targets are comfortably above the $313 close. The consensus mean, at $301, sits below the current price, which reflects the mix of more cautious voices: Citigroup holds Neutral with a $273 target after raising from $190 in August, and BMO Capital sits at Market Perform with $270, both dragging the average down. The bull case rests on Vault CRM momentum and AI-driven cross-sell through the Falcon platform. The bear case points to mature end markets, competitive pressure from better-capitalised vendors, and a residual operational dependency on Salesforce's infrastructure. On valuation, the stock trades at roughly 31x trailing earnings, up about 3 points over the past month, a premium that is not shrinking as the stock approaches the print.

The institutional register shows Vanguard Capital Management adding 2.9 million shares as of September 30, the largest single-quarter build among the top holders. State Street added 3.1 million shares in the same period. Founder Peter Gassner remains the second-largest disclosed holder at 7.6% with no change recorded. On the insider side, the 90-day picture shows net selling of roughly $15 million, but the composition matters: the SVP and General Counsel sold shares under pre-arranged 10b5-1 plans, a scheduled mechanism rather than a discretionary call, and the most notable recent event was a director transaction coded "J" on October 15, which typically reflects a gift or reorganisation rather than a market sale. The insider picture is routine rather than alarming.

The last quarterly print on August 26 produced a one-day move of 14.3%, with the gain extending to 13.8% over the following five sessions, the strongest post-earnings reaction in the available history. Analysts raised targets broadly after that result, revenue up 18% year on year and billings growth of 19% both came in ahead of expectations. The next report is scheduled for November 5. The question the data poses going in is whether the recent target upgrades, with Barclays now at $375 and Baird at $350, reflect a view that the August beat was structural rather than opportunistic, or whether the current $313 price already prices in another strong quarter, leaving the reaction asymmetric to the downside if execution is merely solid rather than exceptional.